Infection prevention for immunocompromised patients: A cross-translational multicentric survey of current organization in France
•In France, access to infection prevention advice for immunocompromised patients is suboptimal.•Only 30% of the physicians interviewed reported on-site access to dedicated consultations.•Most were aware of nationwide guidelines for vaccination of immunocompromised patients.•Guidelines covering all f...
Gespeichert in:
| Veröffentlicht in: | Infectious diseases now (Online) 2024-03, Vol.54 (2), p.104863-104863, Article 104863 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104863 |
|---|---|
| container_issue | 2 |
| container_start_page | 104863 |
| container_title | Infectious diseases now (Online) |
| container_volume | 54 |
| creator | Saade, A. Wyplosz, B. Baldeyrou, M. Paris, C. Tattevin, P. Janssen, C. |
| description | •In France, access to infection prevention advice for immunocompromised patients is suboptimal.•Only 30% of the physicians interviewed reported on-site access to dedicated consultations.•Most were aware of nationwide guidelines for vaccination of immunocompromised patients.•Guidelines covering all fields of infection prevention would be more than welcome.
To evaluate current organization of infection prevention for immunocompromised patients (ICP) at a countrywide level.
Nationwide cross-sectional multicenter study based on an online survey disseminated in 2022 to physicians invested with preventive healthcare missions.
A total of 341 physicians (96% graduates, 32% infectious disease specialists), participated in the survey, with a median age of 40 [35–51] years. On-site access to infection prevention consultations for ICP was reported by 30%, dedicated pre-travel consultations for ICPs by 29%, consultations for infection prevention in solid organ transplant candidates by 16% and return-to-work consultations for ICPs by 6%. Most participants (73%) were aware of nationwide vaccination guidelines for ICP, while 50% felt comfortable using them. Tools for infection prevention advice and ICP vaccination had been developed by 10%, while 89% would have appreciated access to tools developed by others.
Infection prevention for ICPs remains neglected. Guidelines covering all fields of prevention for ICPs would be more than welcome. |
| doi_str_mv | 10.1016/j.idnow.2024.104863 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04457944v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666991924000186</els_id><sourcerecordid>2925033707</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-973fdfadccc615b264deeb5408ea5c2dfc219c2c65a464a0abe38f91f475957f3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EolXpJ0BCPsIhW_-LEyNxWFWUVlqJC5wtrz0GrxJ7sZOtyomPjndTKk49zWj0ezOa9xB6S8mKEiqvdqvgYrpfMcJEnYhe8hfonEkpG6Woevlff4YuS9kRQlhLORPyNTrjPRekV_Qc_bmLHuwUUsT7DAeIp9anjMM4zjHZNO5zGkMBh_dmChUoH_Ea25xKaaZsYhnMUWMGPM7DFGwlcrC4zPkADzh5bOec6xCn_MPE8PtE4xDxTRVbeINeeTMUuHysF-j7zedv17fN5uuXu-v1prG876dGddw7b5y1VtJ2y6RwANu2fgGmtcx5y6iyzMrWCCkMMVvgvVfUi65Vbef5Bfqw7P1pBr3PYTT5QScT9O16o48zIkTbKSEOtLLvF7a-_muGMulqgIVhMBHSXDRTrCWcd6SrKF_QkyEZ_NNuSvQxKb3Tp6T0MSm9JFVV7x4PzNsR3JPmXy4V-LQAUC05BMi62Oq9BRdyjUu7FJ498BdsxKj3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2925033707</pqid></control><display><type>article</type><title>Infection prevention for immunocompromised patients: A cross-translational multicentric survey of current organization in France</title><source>Alma/SFX Local Collection</source><creator>Saade, A. ; Wyplosz, B. ; Baldeyrou, M. ; Paris, C. ; Tattevin, P. ; Janssen, C.</creator><creatorcontrib>Saade, A. ; Wyplosz, B. ; Baldeyrou, M. ; Paris, C. ; Tattevin, P. ; Janssen, C. ; for the SPILF group “Vaccination et Prévention” ; SPILF group “Vaccination et Prévention”</creatorcontrib><description>•In France, access to infection prevention advice for immunocompromised patients is suboptimal.•Only 30% of the physicians interviewed reported on-site access to dedicated consultations.•Most were aware of nationwide guidelines for vaccination of immunocompromised patients.•Guidelines covering all fields of infection prevention would be more than welcome.
To evaluate current organization of infection prevention for immunocompromised patients (ICP) at a countrywide level.
Nationwide cross-sectional multicenter study based on an online survey disseminated in 2022 to physicians invested with preventive healthcare missions.
A total of 341 physicians (96% graduates, 32% infectious disease specialists), participated in the survey, with a median age of 40 [35–51] years. On-site access to infection prevention consultations for ICP was reported by 30%, dedicated pre-travel consultations for ICPs by 29%, consultations for infection prevention in solid organ transplant candidates by 16% and return-to-work consultations for ICPs by 6%. Most participants (73%) were aware of nationwide vaccination guidelines for ICP, while 50% felt comfortable using them. Tools for infection prevention advice and ICP vaccination had been developed by 10%, while 89% would have appreciated access to tools developed by others.
Infection prevention for ICPs remains neglected. Guidelines covering all fields of prevention for ICPs would be more than welcome.</description><identifier>ISSN: 2666-9919</identifier><identifier>EISSN: 2666-9919</identifier><identifier>DOI: 10.1016/j.idnow.2024.104863</identifier><identifier>PMID: 38340891</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Immunocompromised ; Infectious risk ; Life Sciences ; Prevention ; Vaccination</subject><ispartof>Infectious diseases now (Online), 2024-03, Vol.54 (2), p.104863-104863, Article 104863</ispartof><rights>2024 Elsevier Masson SAS</rights><rights>Copyright © 2024 Elsevier Masson SAS. All rights reserved.</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c388t-973fdfadccc615b264deeb5408ea5c2dfc219c2c65a464a0abe38f91f475957f3</cites><orcidid>0000-0003-3625-9092 ; 0000-0003-1131-5385 ; 0000-0003-2989-6413 ; 0000-0001-6417-4980 ; 0000-0003-3617-5411 ; 0000-0002-9779-9044</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38340891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04457944$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Saade, A.</creatorcontrib><creatorcontrib>Wyplosz, B.</creatorcontrib><creatorcontrib>Baldeyrou, M.</creatorcontrib><creatorcontrib>Paris, C.</creatorcontrib><creatorcontrib>Tattevin, P.</creatorcontrib><creatorcontrib>Janssen, C.</creatorcontrib><creatorcontrib>for the SPILF group “Vaccination et Prévention”</creatorcontrib><creatorcontrib>SPILF group “Vaccination et Prévention”</creatorcontrib><title>Infection prevention for immunocompromised patients: A cross-translational multicentric survey of current organization in France</title><title>Infectious diseases now (Online)</title><addtitle>Infect Dis Now</addtitle><description>•In France, access to infection prevention advice for immunocompromised patients is suboptimal.•Only 30% of the physicians interviewed reported on-site access to dedicated consultations.•Most were aware of nationwide guidelines for vaccination of immunocompromised patients.•Guidelines covering all fields of infection prevention would be more than welcome.
To evaluate current organization of infection prevention for immunocompromised patients (ICP) at a countrywide level.
Nationwide cross-sectional multicenter study based on an online survey disseminated in 2022 to physicians invested with preventive healthcare missions.
A total of 341 physicians (96% graduates, 32% infectious disease specialists), participated in the survey, with a median age of 40 [35–51] years. On-site access to infection prevention consultations for ICP was reported by 30%, dedicated pre-travel consultations for ICPs by 29%, consultations for infection prevention in solid organ transplant candidates by 16% and return-to-work consultations for ICPs by 6%. Most participants (73%) were aware of nationwide vaccination guidelines for ICP, while 50% felt comfortable using them. Tools for infection prevention advice and ICP vaccination had been developed by 10%, while 89% would have appreciated access to tools developed by others.
Infection prevention for ICPs remains neglected. Guidelines covering all fields of prevention for ICPs would be more than welcome.</description><subject>Immunocompromised</subject><subject>Infectious risk</subject><subject>Life Sciences</subject><subject>Prevention</subject><subject>Vaccination</subject><issn>2666-9919</issn><issn>2666-9919</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU9v1DAQxS0EolXpJ0BCPsIhW_-LEyNxWFWUVlqJC5wtrz0GrxJ7sZOtyomPjndTKk49zWj0ezOa9xB6S8mKEiqvdqvgYrpfMcJEnYhe8hfonEkpG6Woevlff4YuS9kRQlhLORPyNTrjPRekV_Qc_bmLHuwUUsT7DAeIp9anjMM4zjHZNO5zGkMBh_dmChUoH_Ea25xKaaZsYhnMUWMGPM7DFGwlcrC4zPkADzh5bOec6xCn_MPE8PtE4xDxTRVbeINeeTMUuHysF-j7zedv17fN5uuXu-v1prG876dGddw7b5y1VtJ2y6RwANu2fgGmtcx5y6iyzMrWCCkMMVvgvVfUi65Vbef5Bfqw7P1pBr3PYTT5QScT9O16o48zIkTbKSEOtLLvF7a-_muGMulqgIVhMBHSXDRTrCWcd6SrKF_QkyEZ_NNuSvQxKb3Tp6T0MSm9JFVV7x4PzNsR3JPmXy4V-LQAUC05BMi62Oq9BRdyjUu7FJ498BdsxKj3</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Saade, A.</creator><creator>Wyplosz, B.</creator><creator>Baldeyrou, M.</creator><creator>Paris, C.</creator><creator>Tattevin, P.</creator><creator>Janssen, C.</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-3625-9092</orcidid><orcidid>https://orcid.org/0000-0003-1131-5385</orcidid><orcidid>https://orcid.org/0000-0003-2989-6413</orcidid><orcidid>https://orcid.org/0000-0001-6417-4980</orcidid><orcidid>https://orcid.org/0000-0003-3617-5411</orcidid><orcidid>https://orcid.org/0000-0002-9779-9044</orcidid></search><sort><creationdate>20240301</creationdate><title>Infection prevention for immunocompromised patients: A cross-translational multicentric survey of current organization in France</title><author>Saade, A. ; Wyplosz, B. ; Baldeyrou, M. ; Paris, C. ; Tattevin, P. ; Janssen, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-973fdfadccc615b264deeb5408ea5c2dfc219c2c65a464a0abe38f91f475957f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Immunocompromised</topic><topic>Infectious risk</topic><topic>Life Sciences</topic><topic>Prevention</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saade, A.</creatorcontrib><creatorcontrib>Wyplosz, B.</creatorcontrib><creatorcontrib>Baldeyrou, M.</creatorcontrib><creatorcontrib>Paris, C.</creatorcontrib><creatorcontrib>Tattevin, P.</creatorcontrib><creatorcontrib>Janssen, C.</creatorcontrib><creatorcontrib>for the SPILF group “Vaccination et Prévention”</creatorcontrib><creatorcontrib>SPILF group “Vaccination et Prévention”</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Infectious diseases now (Online)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saade, A.</au><au>Wyplosz, B.</au><au>Baldeyrou, M.</au><au>Paris, C.</au><au>Tattevin, P.</au><au>Janssen, C.</au><aucorp>for the SPILF group “Vaccination et Prévention”</aucorp><aucorp>SPILF group “Vaccination et Prévention”</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infection prevention for immunocompromised patients: A cross-translational multicentric survey of current organization in France</atitle><jtitle>Infectious diseases now (Online)</jtitle><addtitle>Infect Dis Now</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>54</volume><issue>2</issue><spage>104863</spage><epage>104863</epage><pages>104863-104863</pages><artnum>104863</artnum><issn>2666-9919</issn><eissn>2666-9919</eissn><abstract>•In France, access to infection prevention advice for immunocompromised patients is suboptimal.•Only 30% of the physicians interviewed reported on-site access to dedicated consultations.•Most were aware of nationwide guidelines for vaccination of immunocompromised patients.•Guidelines covering all fields of infection prevention would be more than welcome.
To evaluate current organization of infection prevention for immunocompromised patients (ICP) at a countrywide level.
Nationwide cross-sectional multicenter study based on an online survey disseminated in 2022 to physicians invested with preventive healthcare missions.
A total of 341 physicians (96% graduates, 32% infectious disease specialists), participated in the survey, with a median age of 40 [35–51] years. On-site access to infection prevention consultations for ICP was reported by 30%, dedicated pre-travel consultations for ICPs by 29%, consultations for infection prevention in solid organ transplant candidates by 16% and return-to-work consultations for ICPs by 6%. Most participants (73%) were aware of nationwide vaccination guidelines for ICP, while 50% felt comfortable using them. Tools for infection prevention advice and ICP vaccination had been developed by 10%, while 89% would have appreciated access to tools developed by others.
Infection prevention for ICPs remains neglected. Guidelines covering all fields of prevention for ICPs would be more than welcome.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>38340891</pmid><doi>10.1016/j.idnow.2024.104863</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3625-9092</orcidid><orcidid>https://orcid.org/0000-0003-1131-5385</orcidid><orcidid>https://orcid.org/0000-0003-2989-6413</orcidid><orcidid>https://orcid.org/0000-0001-6417-4980</orcidid><orcidid>https://orcid.org/0000-0003-3617-5411</orcidid><orcidid>https://orcid.org/0000-0002-9779-9044</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2666-9919 |
| ispartof | Infectious diseases now (Online), 2024-03, Vol.54 (2), p.104863-104863, Article 104863 |
| issn | 2666-9919 2666-9919 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04457944v1 |
| source | Alma/SFX Local Collection |
| subjects | Immunocompromised Infectious risk Life Sciences Prevention Vaccination |
| title | Infection prevention for immunocompromised patients: A cross-translational multicentric survey of current organization in France |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T20%3A55%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infection%20prevention%20for%20immunocompromised%20patients:%20A%20cross-translational%20multicentric%20survey%20of%20current%20organization%20in%20France&rft.jtitle=Infectious%20diseases%20now%20(Online)&rft.au=Saade,%20A.&rft.aucorp=for%20the%20SPILF%20group%20%E2%80%9CVaccination%20et%20Pr%C3%A9vention%E2%80%9D&rft.date=2024-03-01&rft.volume=54&rft.issue=2&rft.spage=104863&rft.epage=104863&rft.pages=104863-104863&rft.artnum=104863&rft.issn=2666-9919&rft.eissn=2666-9919&rft_id=info:doi/10.1016/j.idnow.2024.104863&rft_dat=%3Cproquest_hal_p%3E2925033707%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2925033707&rft_id=info:pmid/38340891&rft_els_id=S2666991924000186&rfr_iscdi=true |